The trial expansion signals growing confidence in paxalisib's safety profile, but investors should await formal efficacy data (ORR/PFS) before assigning material value. Withdrawal of ASCO abstracts suggests potential IP progress, which could be a positive catalyst if filings materialize. Monitor for next clinical update or patent announcement.
Price Chart
Executive Summary
Kazia Therapeutics announced expansion of its Phase 1b trial of paxalisib in advanced TNBC from 12 to 36 patients following encouraging safety and tolerability data. The company also stated it withdrew ASCO abstracts to protect intellectual property. This is a positive clinical update for an early-stage asset in an underserved indication, but no efficacy data were disclosed and the trial remains small.
Key Facts
- Phase 1b trial enrollment expanded from 12 to 36 patients in paxalisib plus pembrolizumab and chemotherapy for advanced TNBC
- Expansion based on continued encouraging safety, tolerability, and clinical activity data
- ASCO 2026 abstracts withdrawn to protect intellectual property; withdrawal not related to safety concerns
- Additional clinical and translational updates expected in coming months (2026-2027)
Financial Impact
No financial figures disclosed; clinical expansion at early stage with no revenue impact yet
Risk Factors
- Early-stage data may not replicate in larger or later-stage trials
- Withdrawal of ASCO abstracts raises questions about IP strategy; could signal competitive pressure
- No new financial or partnership news; funding for expanded trial not specified
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-060779 |
| Document: ea0292123-6k_kazia.htm | 0001213900-26-060779 |
| Document: 0001213900-26-060779-index-headers.html | 0001213900-26-060779 |
| Document: 0001213900-26-060779-index.html | 0001213900-26-060779 |
| Document: 0001213900-26-060779.txt | 0001213900-26-060779 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 24d ago | SC 13G/A | $9.27 | awaiting T+20 | — | $7.81 (−15.75%) |
Sep 22, 2026 4w ago | 6-K | $10.92 $7.88 | ▼ −27.84% | ▼ −27.28% | $7.81 (−28.48%) |
Sep 1, 2026 7w ago | 6-K | $12.61 $9.60 | ▼ −23.91% | ▼ −23.58% | $7.81 (−38.07%) |
Aug 31, 2026 8w ago | Press Release | $12.63 $9.60 | ▲ +24.03% | ▲ +24.35% | $7.81 (+38.16%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▼ −29.19% | ▼ −29.01% | $7.81 (−43.28%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $7.81 (+43.28%) |
Aug 31, 2026 8w ago | 424B5 | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $7.81 (+43.28%) |
Aug 28, 2026 8w ago | 6-K / 424B5 | $13.58 $9.60 | ▲ +29.31% | ▲ +29.57% | $7.81 (+42.49%) |
Aug 28, 2026 8w ago | 424B5 | $13.58 $9.60 | ▼ −29.31% | ▼ −29.57% | $7.81 (−42.49%) |
Jul 28, 2026 12w ago | 6-K | $12.69 $13.79 | ▲ +8.67% | ▲ +5.29% | $7.81 (−38.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers